| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Edward Mignone, Alistair K Jukes, Rowan Valentine, Richard Allison, Sunita M C De Sous. Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas. Endocrine oncology (Bristol, England). vol 5. issue 1. 2025-02-05. PMID:39906305. |
aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas. |
2025-02-05 |
2025-02-07 |
Not clear |
| Tatiana V Lipina, Huy Giang, Jonathan S Thacker, William C Wetsel, Marc G Caron, Jean Martin Beaulieu, Ali Salahpour, Amy J Ramse. Combination of haloperidol with UNC9994, β-arrestin-biased analog of aripiprazole, ameliorates schizophrenia-related phenotypes induced by NMDAR deficit in mice. The international journal of neuropsychopharmacology. 2024-11-29. PMID:39612588. |
aripiprazole, an atypical antipsychotic drug (apd), acts as a dopamine partial agonist and its combination with haloperidol (a typical apd) was suggested as a potential strategy to improve schizophrenia. |
2024-11-29 |
2024-12-02 |
mouse |
| Rihab Farooq, Huda Zahid, Ammara Shakil Sahibole, Syed Ali Bokhari, Mazin A Mukhta. Complex Pharmacodynamics of Aripiprazole and Haloperidol in Schizophrenia Management: A Case Report. Cureus. vol 16. issue 10. 2024-11-14. PMID:39525142. |
this case report discusses a 44-year-old male with chronic schizophrenia who experienced worsening psychotic symptoms following an interaction between aripiprazole, a partial dopamine agonist, and haloperidol, a first-generation antipsychotic (fga). |
2024-11-14 |
2024-11-17 |
Not clear |
| Haruo Nishijima, Miyuki Nishijima, Chikyo Oyama, Masahiko Tomiyam. Withdrawal Dyskinesia Associated With Aripiprazole in a Child: A Case Report. Cureus. vol 16. issue 7. 2024-08-26. PMID:39184787. |
aripiprazole, a dopamine partial agonist, is one of the most frequently used atypical antipsychotics in children. |
2024-08-26 |
2024-08-28 |
Not clear |
| Renata S Auriemma, Roberta Scairati, Rosa Pirchio, Guendalina Del Vecchio, Sara Di Meglio, Davide Menafra, Rosario Pivonello, Annamaria Cola. Cardiometabolic effects of hypoprolactinemia. Reviews in endocrine & metabolic disorders. 2024-07-30. PMID:39078526. |
this evidence has been collected mainly in patients on chronic treatment with dopamine agonists for prl excess due to a prl-secreting pituitary tumour, and less frequently in those receiving the atypical antipsychotic aripiprazole. |
2024-07-30 |
2024-08-02 |
human |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
the review discusses aspects of the use of atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia using the model of aripiprazole, a partial agonist of dopamine receptors. |
2024-04-27 |
2024-04-30 |
Not clear |
| Itsuki Terao, Wakako Kodam. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treatment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis. Journal of clinical psychopharmacology. 2024-04-19. PMID:38639435. |
the augmentative antidepressant effects of dopamine partial agonists (aripiprazole, brexpiprazole, and cariprazine) for treatment-resistant depression have been compared in a previous network meta-analysis. |
2024-04-19 |
2024-04-21 |
Not clear |
| Wei Su, Dan Zhao, Hongmei Zhao, Wanhong Zheng, Wangxin Zhan. A 28-Year-Old Man with Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, and Dissociative Identity Disorder Responding to Aripiprazole Augmentation of Clomipramine Combined with Psychoeducation and Exposure and Response Prevention. The American journal of case reports. vol 24. 2023-12-15. PMID:38100391. |
conclusions the case illustrates both how impairing the comorbidity of ocd, ptsd, and did can be and how concurrent use of tricyclic antidepressant (tca) clomipramine and partial dopamine agonist aripiprazole, together with psychoeducation and erp, can improve outcomes when other treatment choices fail to be effective. |
2023-12-15 |
2023-12-18 |
Not clear |
| Bernhard T Baun. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current medical research and opinion. 2023-11-24. PMID:37999650. |
dopamine d2 partial agonists, one of which is aripiprazole, exhibit favorable tolerability and safety properties. |
2023-11-24 |
2023-11-29 |
Not clear |
| Autumn R Schultz, Sarina Singh, Carolyn E Linek-Rajapaksha, Heather R Goode, Adam J Fusic. A Case of Neuroleptic Malignant Syndrome in the Context of Lithium Toxicity and Aripiprazole Use. Clinical neuropharmacology. 2023-10-24. PMID:37874611. |
considerable evidence, however, has suggested that atypical antipsychotics are associated with nms, including the partial dopamine agonist, aripiprazole. |
2023-10-24 |
2023-11-08 |
Not clear |
| Tarun Gupta, Varinder Singh, Mohamed Hefnawy, Mohammed M Alanazi, Bader Alsuwayt, Atul Kabra, Amit Kumar, Chirag Pasricha, Ravinder Sing. Ameliorating the Role of Aripiprazole in Memory Deficits Induced by Intracerebroventricular Streptozotocin-Induced Dementia of Alzheimer's Type. ACS omega. vol 8. issue 28. 2023-07-24. PMID:37483219. |
this study aimed to investigate the role of aripiprazole, a dopamine d2 and 5-ht1a selective receptors' activator, in the restoration of memory deficit induced by streptozotocin in mice. |
2023-07-24 |
2023-08-14 |
mouse |
| Fumiaki Yamasaki, Nobuhisa Kanahara, Yusuke Nakata, Shinji Koyoshi, Yuta Yanagisawa, Takeru Saito, Takahiro Oiwa, Masanobu Kogure, Tsuyoshi Sasaki, Taisuke Yoshida, Hiroshi Kimura, Masaomi Iy. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. Journal of psychopharmacology (Oxford, England). 2023-07-03. PMID:37395368. |
several studies have reported that a switch to the dopamine partial agonist (dpa) aripiprazole (arp), especially when the switch is abrupt, is likely to fail and sometimes worsen psychosis in schizophrenia patients already under high-dose antipsychotic treatment. |
2023-07-03 |
2023-08-14 |
Not clear |
| Sanja Strbe, Ivan Maria Smoday, Ivan Krezic, Luka Kalogjera, Vlasta Vukovic, Helena Zizek, Slaven Gojkovic, Hrvoje Vranes, Ivan Barisic, Suncana Sikiric, Marijan Tepes, Katarina Oroz, Filip Brkic, Martin Drinkovic, Lidija Beketic Oreskovic, Jelena Popic, Alenka Boban Blagaic, Anita Skrtic, Mario Staresinic, Sven Seiwerth, Predrag Sikiri. Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy. Pharmaceuticals (Basel, Switzerland). vol 16. issue 6. 2023-06-28. PMID:37375736. |
in rats with complete calvariectomy, medication (bpc 157 10 µg/kg, 10 ng/kg ip or ig) was given 5 min after distinctive dopamine agents (mg/kg ip) (haloperidol (5), fluphenazine (5), clozapine (10), risperidone (5), olanzapine (10), quetiapine (10), or aripiprazole (10), domperidone (25), amphetamine (10), and combined amphetamine and haloperidol) and assessed at 15 min thereafter. |
2023-06-28 |
2023-08-14 |
rat |
| Iveta Vojtechova, Klara Tuckova, Radomir Juza, Ales Stuchlik, Eduard Kelemen, Jan Korabecny, Ondrej Soukup, Tomas Petrase. Dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating D Progress in neuro-psychopharmacology & biological psychiatry. 2023-06-28. PMID:37379895. |
dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating d dopamine type 2 receptors (d |
2023-06-28 |
2023-08-14 |
Not clear |
| Janusz K Rybakowsk. Application of Antipsychotic Drugs in Mood Disorders. Brain sciences. vol 13. issue 3. 2023-03-29. PMID:36979224. |
third-generation antipsychotics (tgas) started with aripiprazole, a partial dopamine d2 receptor agonist, followed by brexpiprazole, lurasidone, cariprazine, and lumateperone. |
2023-03-29 |
2023-08-14 |
human |
| Octavian Vasili. The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders. Frontiers in psychiatry. vol 14. 2023-03-06. PMID:36873203. |
allelic variability in genes encoding dopamine d2, d3, and serotonin, 5ht2a, 5ht2c receptors, comt, bdnf, and dopamine transporter dat1 was also associated with different adverse events or variations in the clinical efficacy of aripiprazole. |
2023-03-06 |
2023-08-14 |
Not clear |
| Mahyar Etminan, Mohit Sodhi, Bruce Carleto. Reply: Misidentified Dopamine Agonists Undermine Investigation Into Aripiprazole Link With Impulse Control Disorders. Journal of clinical psychopharmacology. 2023-02-23. PMID:36821462. |
reply: misidentified dopamine agonists undermine investigation into aripiprazole link with impulse control disorders. |
2023-02-23 |
2023-08-14 |
Not clear |
| David M Gardne. Misidentified Dopamine Agonists Undermine Investigation Into Aripiprazole Link With Impulse Control Disorders. Journal of clinical psychopharmacology. 2023-02-23. PMID:36821484. |
misidentified dopamine agonists undermine investigation into aripiprazole link with impulse control disorders. |
2023-02-23 |
2023-08-14 |
Not clear |
| Adriana Stelmach, Katarzyna Guzek, Alicja Rożnowska, Irena Najbar, Anna Sadakierska-Chud. Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacological reports : PR. 2022-12-16. PMID:36526889. |
aripiprazole (ari) is classified as a third-generation antipsychotic drug with a high affinity for dopamine and serotonin receptors. |
2022-12-16 |
2023-08-14 |
Not clear |
| Constance Bordet, Philippe Garcia, Francesco Salvo, Anthony Touafchia, Michel Galinier, Agnès Sommet, François Montastru. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. Psychopharmacology. 2022-12-14. PMID:36515735. |
while meta-analyses of clinical trials found that lurasidone and partial dopamine agonists (brexpiprazole and aripiprazole) were the antipsychotics less likely to cause qtc prolongation, and sertindole, amisulpride, and ziprasidone were the most frequently associated with this adverse drug reaction; no real-world studies have investigated this risk between the different antipsychotics. |
2022-12-14 |
2023-08-14 |
Not clear |